6-chloro-2,3-dimethylquinazolin-4(3H)-one | 7012-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-chloro-2,3-dimethylquinazolin-4(3H)-one
• 英文别名: 6-Chlor-2,3-dimethyl-3H-benzo<1,3>diazin-4-on；6-chloro-2,3-dimethyl-3H-quinazolin-4-one；6-Chloro-2,3-dimethylquinazolin-4-one
• CAS: 7012-86-4
• 化学式: C₁₀H₉ClN₂O
• 分子量: 208.647
• InChiKey: SEFLKLFXBGNQHX-UHFFFAOYSA-N

物化性质

• 熔点：
  151-152 °C
• 沸点：
  350.2±44.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以73%的产率得到6-chloro-2,3-dimethylquinazolin-4(3H)-one
  参考文献：
  名称：

  4(3H)-Quinazolinones from the Reaction ofN-Arylnitrilium Salts with Isocyanates

  摘要：

  N-Arylnitrilium 盐 1 与异氰酸酯 2 反应生成 4(3H)-喹唑啉酮 4 的盐 3，用碱可从中得到化合物 4。据报道，一种异氰酸酯与一种硝基鎓盐发生了复分解反应。

  DOI：

  10.1055/s-1992-26203

文献信息

• Phosphorous acid functionalized polyacrylonitrile fibers with a polarity tunable surface micro-environment for one-pot C–C and C–N bond formation reactions
  作者：Gang Xu、Lu Wang、Mengmeng Li、Minli Tao、Wenqin Zhang

  DOI：10.1039/c7gc02935g

  日期：——

  hydrophobic surface micro-environment of the fiber catalysts is proven to promote the catalytic activities impressively in cyclocondensation of β-ketoesters with 2-aminobenzamides, the Knoevenagel condensation as well as the multi-component Biginelli reactions in green solvents. Both the surface synergy of the catalytic sites and hydrophobic auxiliary groups (benzyl or n-butyl) in the surface of fiber catalysts

  纤维催化剂的制备和应用引起了人们的广泛关注。然而，尽管特别重要，但是关于纤维催化剂的微环境对催化活性的影响的研究是有限的。在这项工作中，报道了一种通过疏水基团合成极性可调的表面微环境的磷酸官能化聚丙烯腈纤维的新策略，用于一锅式C–C和C–N键形成反应。事实证明，纤维催化剂的特殊疏水表面微环境可显着提高β-酮酸酯与2-氨基苯甲酰胺的环缩合，Knoevenagel缩合以及在绿色溶剂中的多组分Biginelli反应的催化活性。催化位点的表面协同作用和疏水性辅助基团（苄基或纤维催化剂表面的正丁基）和反应介质中的界面加速在高效提高催化活性方面起着重要作用。因此，提出了一种表面协同机理来解释微环境效应。另外，可以使用镊子将纤维催化剂简单地从反应体系中分离出来，并直接用于下一循环而无需进一步处理。重要的是，即使在水或乙醇中进行10个反应循环后，其催化活性也不会显着降低。结果表明，磷酸功能化纤维显示出绿色和可持续的工业生产潜力。
• [EN] PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：GILEAD SCIENCES INC

  公开号：WO2014201409A1

  公开（公告）日：2014-12-18

  The present disclosure provides phosphatidylinositol 3 -kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本公开提供式(I)的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药学上可接受的盐或异构体，其中n，m，R1，R2，R4和R3如本文所定义。这些化合物可用于治疗由一个或多个PI3K亚型介导的疾病，例如PI3Kδ。本公开还提供包括式(I)的化合物或其药学上可接受的盐或异构体的制药组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K亚型介导的疾病，例如PI3Kδ的方法。
• PLATELET ADP RECEPTOR INHIBITORS
  申请人：SCARBOROUGH ROBERT M.

  公开号：US20080194597A1

  公开（公告）日：2008-08-14

  Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  化合物的式子(I)到(VIII)，其中更特别地包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，这些衍生物是有效的血小板ADP受体抑制剂。这些衍生物可以用于各种制药组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成有关的疾病非常有效。本发明还涉及一种预防或治疗哺乳动物血栓形成的方法，包括给予化合物的式子(I)到(VIII)或其药学上可接受的盐的治疗有效量。
• Platelet ADP receptor inhibitors
  申请人：Portola Pharmaceuticals, Inc.

  公开号：EP2314593A1

  公开（公告）日：2011-04-27

  Novel compounds of formulae (I), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.

  式(I)的新型化合物，其中特别包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰基胍衍生物、硫酰基磺酰胺衍生物和酰基磺酰胺衍生物，它们是有效的血小板ADP受体抑制剂。这些衍生物可用于各种药物组合物中，对预防和/或治疗心血管疾病，尤其是与血栓形成有关的疾病特别有效。本发明还涉及将有效量的式（I）化合物或其药学上可接受的盐用于制造预防或治疗哺乳动物血栓形成的药物组合物。
• A practical and versatile approach toward a one-pot synthesis of 2,3-disubstituted 4(3H)-quinazolinones
  作者：Minoo Dabiri、Peyman Salehi、Mahboobeh Bahramnejad、Mohsen Alizadeh

  DOI：10.1007/s00706-010-0341-1

  日期：2010.8

  An effective one-pot three-component route to 4(3H)-quinazolinones from commercially available starting materials is reported. Thus, isatoic anhydride reacted with ammonium acetate or primary amines and aldehydes in the presence of iodine to produce the corresponding quinazolinone derivatives in moderate to good yields.